- LLY dividends total $6.92 annually per share, producing a 0.57% forward yield at $1,213.91.
- Lilly’s dividend has grown at roughly 15.2% annually over three and five years.
- Shares trade 2.8% below their 52-week high, leaving investors with a lower yield than the five-year average.
Dividend Snapshot
Eli Lilly (LLY) pays a quarterly dividend of $1.73 per share, unchanged from the prior payment. That equals an annualized payout of $6.92 per share and a forward dividend yield of just 0.57% at a share price of $1,213.91.
For perspective, an investor buying 100 LLY shares would commit roughly $121,391 and receive about $692 annually in dividends before taxes. The next listed payment date is September 10, 2026, and the supplied dividend calendar lists an August 14 ex-dividend date.
Dividend Growth Drives the LLY Investment Case
Lilly’s dividend has compounded at an annual rate of about 15.4% over one year, 15.2% over three years, and 15.2% over five years. Its 10-year dividend-growth rate is also a strong 12.3%.
The company has paid cumulative dividends of $65.95 per share over its history, while its dividend per payment has increased more than sixfold over the past decade. Lilly’s Chowder score, which combines yield and five-year dividend growth, is 15.8, although it is driven primarily by payout growth rather than immediate income.
Premium Valuation Limits Current Income
LLY shares trade near their 52-week high of $1,249.45, with the current price only about 2.8% below that level. The stock’s trailing price-to-earnings ratio is 40.8, a demanding valuation for dividend investors.
The current 0.57% LLY dividend yield is below Lilly’s five-year average yield of approximately 0.81%. Investors therefore receive less dividend income for every dollar invested today than they typically have over the past five years.
Lilly’s cardiometabolic portfolio, including Mounjaro and Zepbound, has supported expectations for continued earnings and cash-flow expansion. However, premium valuations create greater downside risk if growth slows, pricing pressure increases, or market expectations become less optimistic.
LLY Dividends Suit Growth-Focused Investors
Income-focused investors may find Lilly’s 0.57% yield insufficient for near-term cash-flow needs. Long-term dividend-growth investors may view the low starting yield as a trade-off for historically strong payout growth.
New buyers may consider staged purchases with shares near their 52-week high and trading at a premium valuation. Current holders comfortable with the valuation and pharmaceutical-industry risks may find the dividend growth profile supportive of holding.
Eli Lilly remains a high-quality dividend-growth story rather than a high-yield income stock. Patient investors may benefit from continued payout growth, while value-conscious buyers may prefer to wait for a better entry point and higher yield.
